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OBJECTIVE—In human adipocytes, the cAMP-dependent path-
way mediates signals originating from -adrenergic activation,
thus playing a key role in the regulation of important metabolic
processes, i.e., lipolysis and thermogenesis. Cyclic AMP effects
are mainly mediated by protein kinase A (PKA), whose R2B
regulatory isoform is the most expressed in mouse adipose
tissue, where it protects against diet-induced obesity and fatty
liver development. The aim of the study was to investigate
possible differences in R2B expression, PKA activity, and lipoly-
sis in adipose tissues from obese and nonobese subjects.
RESEARCH DESIGN AND METHODS—The expression of
the different PKA regulatory subunits was evaluated by immuno-
histochemistry, Western blot, and real-time PCR in subcutaneous
and visceral adipose tissue samples from 20 nonobese and 67
obese patients. PKA activity and glycerol release were evaluated
in total protein extract and adipocytes isolated from fresh tissue
samples, respectively.
RESULTS—Expression techniques showed that R2B was the
most abundant regulatory protein, both at mRNA and protein
level. Interestingly, R2B mRNA levels were signiﬁcantly lower in
both subcutaneous and visceral adipose tissues from obese than
nonobese patients and negatively correlated with BMI, waist
circumference, insulin levels, and homeostasis model assess-
ment of insulin resistance. Moreover, both basal and stimulated
PKA activity and glycerol release were signiﬁcantly lower in
visceral adipose tissue from obese patients then nonobese
subjects.
CONCLUSIONS—Our results ﬁrst indicate that, in human adi-
pose tissue, there are important BMI-related differences in R2B
expression and PKA activation, which might be included among
the multiple determinants involved in the different lipolytic
response to -adrenergic activation in obesity. Diabetes 58:
620–626, 2009
C
yclic AMP is implicated in the regulation of a
variety of cell functions that are, at least in part,
related to protein phosphorylation through the
activation of protein kinase A (PKA). In addition
to the control of differentiated functions, such as motility,
secretion, metabolism, differentiation, synaptic transmis-
sion, and ion channel activities, cAMP inhibits or stimu-
lates cell proliferation depending on the cell type. In
human adipocytes, the cAMP-dependent pathway medi-
ates signals originating from the activation of -adrenergic
receptors, thus playing a key role in the regulation of
important metabolic processes, such as lipolysis and ther-
mogenesis. Cyclic AMP effects are mainly mediated by
PKA, a tetrameric enzyme composed of two catalytic
subunits associated with two regulatory subunits. There
are four different regulatory subunit genes and proteins
(R1A, R1B, R2A, and R2B) expressed with a tissue-speciﬁc
pattern and exerting distinct roles in cell differentiation
and growth control (1). Dramatic changes in the propor-
tion of the two PKA regulatory subunits, R1 and R2, occur
during ontogenic development, differentiation processes,
and neoplastic transformation, indicating distinct roles for
these isoenzymes in cell homeostasis and growth control
(2,3). In the past few years, many studies seem to indicate
that signaling via PKA plays an important role in regulating
metabolism and body weight (4). In particular, the R2B
isoform has been demonstrated to be, in mice, the most
expressed in three tissues known to regulate energy
homeostasis, i.e., brown adipose tissue, white adipose
tissue, and brain (4,5). In general, the activation of the
holoenzyme PKA in fat is now thought to decrease obesity,
as demonstrated in both genetically obese (ob/ob) (6,7)
and diet-induced obese mice (8). As far as the R2B subunit
is concerned, studies in mice lacking this speciﬁc PKA
subunit have revealed an unexpected role for this protein
in regulating energy balance (5). R2B knockout mice
(RIIß
/) remain remarkably lean, even when challenged
with a high-fat diet (5). These animals have increased
metabolic activity, manifested by increases in body tem-
perature, uncoupling protein 1 concentration, and lipid
hydrolysis. Biochemical studies have shown that loss of
R2B is compensated by the increased R1A regulatory
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620 DIABETES, VOL. 58, MARCH 2009subunit, which is more sensitive to cAMP activation and
results in a net increase in basal PKA activity (9).
In contrast to this increasing knowledge in mice, little is
known about the differential role played by the different
PKA regulatory subunits in humans. Two studies from the
same group have described lower R2B levels in adipose
tissues from 10 normal-weight women affected with poly-
cystic ovary syndrome (PCOS) when compared with 13
matched control women and associated this event with
lipolytic catecholamine resistance and insulin resistance
in these patients (10,11). We present the ﬁrst study evalu-
ating the relative expression of the different PKA isoforms
in a large series of human adipose tissues. Our results
indicate important BMI-related differences in R2B expres-
sion and PKA activation, which might play a role in the
different lipolytic response to -adrenergic activation in
obese and nonobese subjects.
RESEARCH DESIGN AND METHODS
Patients, adipose tissues, and cell cultures. The study included 87 human
subcutaneous and visceral adipose tissue samples from 67 obese patients
(BMI 30 kg/m
2) and 20 age- and sex-matched nonobese subjects (BMI 30
kg/m
2), collected during bariatric surgery and abdominal surgical procedure
for benign disease (elective cholecystectomy), respectively. The subjects were
all Caucasians and, aside from the surgery indication, were all apparently
healthy, with no history of alcohol overconsumption. No patient had overt
diabetes or lipodystrophia and no one was under antihypertensive treatment
with -blockers. Height, weight, waist circumference, and systolic and dia-
stolic blood pressures were measured the day before surgery. A fasting
morning blood sample was obtained from all patients for measurement of
glucose and insulin, and the samples were analyzed by the hospital’s routine
chemistry laboratory. Insulin resistance degree was determined using the
homeostasis model assessment [HOMA-IR  fasting insulin (mU/l)  fasting
glucose (mmol/l)/22.5]. The study was approved by the local ethics committee
of Fondazione Ospedale Maggiore Policlinico IRCCS, Milan. All subjects gave
their informed consent before participation.
Small sample fragments were ﬁxed for immunohistochemistry (IHC), part
of the tissues was digested with collagenase type II (Sigma-Aldrich, Milan,
Italy) for the isolation of adipocytes, while the remaining tissue was quickly
frozen for subsequent molecular analysis. Adipocytes separation from prea-
dipocytes and other cell types was based on cellular dimension and density.
Brieﬂy, adipose tissue biopsies (0.4–1.5 g) were digested in an albumin
solution containing collagenase (DMEM F12 containing Hepes 15 mmol/l,
Biotin 33 mol/l, BSA 2%, collagenase type II 750 g/ml, antibiotics; all
reagents from Sigma-Aldrich) at 37°C for 2 h. The digested tissue was passed
on a 100-m ﬁlter (nylon cell strainer; BD Transduction Laboratories, Lexing-
ton, U.K.) to eliminate undigested material. The obtained cell suspension was
centrifugated (1,000 rpm, 15 min). After this centrifugation step, preadipo-
cytes are pelletted at the bottom of the tube, while adipocytes are found on the
surface as a ring due to their low density. At this step, the adipocyte ring is
transferred to a new tube, and isolated adipocytes are ready to be used for
subsequent analysis. Pelletted preadipocytes are resuspended in culture
medium (DMEM F12 containing Hepes 15 mmol/l, Biotin 33 mol/l, FBS 10%,
antibiotics) and passed on a 40-m ﬁlter to eliminate eventually remaining
adipocytes and other cell types on the basis of their different diameter. After
ﬁltration, the cell suspension is centrifugated (1,000 rpm, 15 min), and
pelletted preadipocytes are resuspended in culture media and used for
subsequent experiments.
Immunohistochemistry. Adipose tissue samples were processed for IHC, as
previously reported (10). Speciﬁc monoclonal antibodies for PKA R1A, PKA
R2A, and PKA R2B were used under the conditions speciﬁed by the manufac-
turer (BD Transduction Laboratories, Lexington, U.K.). Antigen-antibody
detection was performed using the DAKO ChemMate En Vision detection kit
(DAKO A/S, Glostrup, Denmark) according to the manufacturer’s instructions.
Sections were stained with 3,3-diaminobenzidine substrate, counterstained
with Meyer hematoxylin and slides prepared for light microscopy examina-
tion, as previously reported (12). Negative controls were obtained by occult-
ing the primary antibody or by using an unrelated mouse monoclonal
antibody.
Western blot. Western blotting was performed as previously described (12)
on total protein extracts from 40 visceral adipose tissue samples (20 from
nonobese and 20 from obese subjects). Brieﬂy, total proteins extracted from
adipose tissue samples were quantiﬁed using the BCA assay protein kit
(Pierce, Rockford, IL), and 20 g was resolved by 10% SDS-PAGE and
transferred onto nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA). PKA R1A, PKA R2B, and PKA R2A were detected using the same speciﬁc
monoclonal antibodies used for IHC and detected by the chemiluminescent
method, and the resulting bands were evaluated by imaging densitometer
(BioRad GS-670) (12). Experiments were repeated at least twice.
mRNA quantitative analysis. Total RNA was isolated from tissue specimens
using a commercial kit (Qiagen Rneasy mini kit) according to the manufac-
turer’s instructions, and 200 ng RNA was reverse-transcribed (Superscript
Invitrogen S.R.L., Italy). PKA R1A, PKA R2A, and PKA R2B mRNA levels were
evaluated in adipose tissue samples by real-time quantitative RT-PCR based
on TaqMan methodology, using a ready-to-use assay (identiﬁcation numbers
Hs00267597_m1, Hs00177760_m1, and Hs00176966_m1, respectively; Assay-
on-Demand Gene Expression Products, Applied Biosystems, Foster City, CA),
according to the manufacturer’s instructions, and the ABI Prism 7700 Se-
quence Detection System (Applied Biosystems). PKA R1A, R2A, and R2B
mRNA expression were determined applying the 	Ct method, as previously
described (12,13). To normalize the amount of total RNA added to each
reaction mixture, we quantiﬁed as the internal RNA control the GUSB mRNA
(14). The level of CD68 mRNA was also evaluated to quantify blood contam-
ination and inﬂammatory inﬁltration. Similar results were obtained with or
without normalization with CD68 mRNA levels, thus indicating absent or poor
contamination in all samples.
PKA activity. PKA activity was measured, as previously reported (12), using
a nonradioactive PKA kinase activity assay kit (Stressgen, Victoria BC,
Canada) in 1 g protein extracts from human subcutaneous and visceral
adipose tissue samples (20 nonobese and 20 obese subjects). The assay is
based on a solid-phase enzyme-linked immunosorbent assay that uses a
speciﬁc synthetic peptide as a substrate for PKA (kempeptide) and a poly-
clonal antibody that recognizes the phosphorylated form of the substrate. PKA
activity reﬂects the enzymatic activity after stimulation with 5 mol/l cAMP,
free PKA activity represents basal activity in the absence of cAMP stimulation,
and total PKA activity is calculated as the difference between cAMP-stimu-
lated PKA and the PKA inhibited by the protein kinase inhibitor (PKI) (5
mol/l). Data obtained from different assays were normalized by including the
same control sample in each experiment.
Glycerol release. Adipocytes were isolated from 40 visceral and subcutane-
ous human fresh adipose tissue samples (20 obese and 20 nonobese patients)
and seeded in 96-well plates. The amount of material used for glycerol release
evaluation was determined on digested tissue weight and the results were
then normalized for DNA quantiﬁcation. Glycerol release in the medium
(Assay Buffer) was measured using a commercial kit (Adipolysis assay kit;
Chemicon) according to the manufacturer’s instructions. Brieﬂy, after 2 h
incubation at 37°C in the assay buffer (Hank’s balanced salt solution, 2% BSA)
with or without the addition of 1 mol/l isoproterenol or 100 mol/l
8-Cl-cAMP, glycerol reagent solution was added to a cell-free aliquot of the
incubation medium. Glycerol released to the medium is phosphorylated by
ATP by glycerol kinase. Glycerol-1-phosphate (G-1-P) is then oxidized by
glycerol phosphate oxidase with the production of H2O2, which reacts with
dyes contained in the reagent solution, producing a quinoeimine dye that
shows an absorbance maximum at 540 nm. The increase in the absorbance at
540 nm is directly proportional to the glycerol concentration of the sample.
Statistical analysis. Variables that were not normally distributed were
log-transformed. Paired t test and two-way ANOVA were used to compare the
expression levels of PKA regulatory subunit mRNA in subcutaneous and
visceral adipose tissue where indicated and two sample t tests to examine the
differences between obese and nonobese subjects. Pearson’s correlation
analyses were used to evaluate bivariate relationships (14). Partial correlation
was used to explore if correlations between PKA R2B expression and insulin
resistance were independent of obesity. Data are expressed as means 
 SD.
P 0.05 was considered statistically signiﬁcant. All analyses were performed
using SPSS version 16.0 (SPSS, Chicago, IL).
RESULTS
PKA regulatory subunit expression in human subcu-
taneous and visceral adipose tissues. Immunohisto-
chemistry performed on human adipose tissue samples
from both nonobese and obese subjects included in the
study showed a strong immunopositivity for PKA R2B,
whereas the other PKA regulatory subunits analyzed (R2A
and R1A) were either absent or expressed at very low
levels (Fig. 1A).
Western blot analysis was performed on total protein
extracts from 40 visceral adipose tissue samples (20 from
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conﬁrmed the prevalence of the PKA R2B subunit over
R1A and R2A subunits, which were either absent or
detected at extremely low levels (Fig. 1C). Moreover,
quantiﬁcation of the resulting bands showed that PKA R2B
protein was signiﬁcantly lower in adipose tissues from
obese patients compared with those from nonobese pa-
tients (P  0.01, Fig. 1B and C).
The transcriptional level of PKA R subunits was ana-
lyzed by real-time RT-PCR in total RNA extracted from all
the adipose tissue samples included in the study. This
analysis conﬁrmed that in all samples, PKA R2B was the
predominant PKA regulatory subunit also at the mRNA
level, whereas PKA R1A and particularly PKA R2A were
expressed at lower levels. However, mRNA levels of the
three regulatory subunits were signiﬁcantly lower in obese
subjects than in nonobese subjects (PKA 1A: P  0.00005;
PKA 2A: P  0.01; PKA 2B: P  0.0001). In particular, the
reduced expression of PKA R2B and R1A subunit mRNA in
obese versus nonobese subjects was strongly signiﬁcant in
both subcutaneous (PKA 2B: P  0.001; PKA 1A: P 
0.001) and visceral (PKA 2B: P  0.01; PKA 1A: P  0.05)
adipose tissue samples, whereas PKA R2A expression was
extremely low in all samples, with a tendency to be lower
in those from obese patients (P  0.06) (Fig. 2). When
comparing the expression level of PKA R in visceral versus
subcutaneous adipose tissue, no difference in PKA R
expression was observed in samples from nonobese sub-
jects, whereas visceral adipocytes from obese patients
expressed higher levels of PKA R2B and R1A when com-
pared with the corresponding subcutaneous adipose tissue
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FIG. 1. A: Immunostaining for the three PKA regulatory subunits (R1A, R2A, and R2B) performed in a human subcutaneous adipose tissue, as a
representative example (upper panels). Similar data were obtained in the other 84 subcutaneous and visceral samples (from obese and nonobese
subjects). All photomicrographs are shown at an original magniﬁcation of 25. B: PKA R2B protein representative Western blot analysis performed
in human subcutaneous adipose tissue samples from four obese and four nonobese subjects, as representative examples of the 40 samples analyzed.
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FIG. 2. PKA regulatory subunit (R1A, R2A, and R2B) mRNA expression
in human adipose tissue from obese and nonobese subjects as assessed
by real-time PCR. Data are expressed as mRNA relative quantities.
Overall, obese subjects express signiﬁcantly lower levels of R1A and
R2B subunit mRNA than nonobese subjects, and a similar expression
pattern is observed both in visceral (A) and subcutaneous (B) adipose
tissue samples (adipose tissue from obese versus nonobese subjects:
*P < 0.01; §P < 0.05; #P < 0.001).
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 1.5 and 3.67 
 0.9 in
subcutaneous vs. 4.82 
 1.8 and 8.72 
 2.2 in visceral
adipose tissue, P  0.013 and P  0.019, respectively).
Correlation between PKA R2B mRNA levels and clin-
ical parameters. The main clinical data of obese and
nonobese patients included in this study are summarized
in Table 1. We correlated the expression of PKA regulatory
subunits with clinical parameters. In particular, following
the demonstration of low R2B protein levels in patients
with PCOS (10,11), a syndrome characterized by insulin
resistance, we searched for correlations between PKA
regulatory subunit expression and insulin levels, as well as
HOMA-IR as a surrogate marker of insulin resistance.
Statistical analysis demonstrated that PKA R2B expression
was strongly negatively correlated to BMI, waist circum-
ference, insulin levels, and HOMA-IR (subcutaneous: r 
0.280, r  0.296, r  0.269, r  0.255, respectively;
P  0.01; visceral: r  0.298, r  0.267, r  0.240, r 
0.245, respectively; P  0.01), with these last two corre-
lations being independent of BMI (Fig. 3). No correlation
was observed with age and/or the presence or the absence
of menopause, and no difference was detected between
males and females in the two groups (obese and nono-
bese).
PKA and lipolytic activity in human subcutaneous
and visceral adipose tissues. PKA activity was evalu-
ated in 1 g total protein extracts from both visceral and
subcutaneous adipose tissue samples of 20 nonobese and
20 obese subjects. Basal PKA activity was reduced in
visceral and subcutaneous protein samples from adipo-
cytes of obese subjects compared with what was observed
in nonobese subjects. However, this difference was statis-
tically signiﬁcant only for visceral adipose tissue (visceral:
P  0.017; subcutaneous: P  0.464).
In all the samples analyzed, enzymatic PKA activity was
signiﬁcantly stimulated by cAMP treatment. The same
results were obtained after treatment with 8-Cl-cAMP, a
cAMP analog able to selectively activate PKA type 2 (2),
whereas the addition of the PKA inhibitor PKI (5 mol/l)
signiﬁcantly reduced cAMP-stimulated activity, as ex-
pected (Fig. 4). Interestingly, the cAMP- and 8-Cl-cAMP–
induced stimulation of PKA activity in proteins from
visceral adipose tissue of obese patients was signiﬁcantly
lower than that observed in samples from nonobese
patients, whereas the difference did not reach statistical
signiﬁcance in subcutaneous adipose tissues (Fig. 4).
Lipolytic activity was measured by evaluating the quan-
tity of glycerol released by adipocytes in culture medium.
Glycerol release was measured both at basal level and
after stimulation of -adrenergic receptor by isoproterenol
TABLE 1
Clinical data of obese and nonobese subjects included in this
study
Obese Nonobese P
n 67 20
Age (years) 46.4 
 11.7 41.9 
 10.2 NS
Sex (F:M) 53:14 14:6 NS
BMI (kg/m
2) 37.07 
 5.3 22.8 
 3.9 0.001
Waist circumference (cm) 116 
 12.6 88.3 
 8.2 0.001
Systolic blood pressure
(mmHg) 143 
 18 122 
 21 NS
Diastolic blood pressure
(mmHg) 94 
 13 83 
 9N S
Plasma insulin (mU/l) 18 
 10 11.5 
 6 0.05
Plasma glucose (mmol/l) 5.2 
 2.4 4.9 
 0.8 NS
HOMA-IR 3.9 
 1.1 2.4 
 0.4 0.01
Data are means 
 SD unless otherwise indicated.
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FIG. 3. Dot plots showing the negative correlations between BMI (A) and
HOMA-IR (B) and PKA R2B mRNA expression in subcutaneous fat from
87 subjects (r  0.280, P  0.005, and r  0.255, P  0.008, respec-
tively). Similar results were obtained when considering visceral fat.
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FIG. 4. PKA activity measured (relative ﬂuorescence units [RFU]) in
cell extracts from visceral (A) and subcutaneous (B) adipose tissue
samples from obese and nonobese patients. cAMP and 8-Cl-cAMP
increased PKA activity both in obese and nonobese subject adipocytes,
with this stimulation being inhibited by the PKA inhibitor PKI. Basal
and stimulated PKA activity was signiﬁcantly lower in visceral adipose
tissue from obese patients than in samples from nonobese subjects.
*P < 0.05 vs. basal; #P < 0.05 vs. cAMP stimulated; §P < 0.05 vs.
nonobese subjects.
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ulation of cAMP pathway by isoproterenol or 8-Cl-cAMP
was able to induce an increase in glycerol release both in
visceral and subcutaneous adipocytes from obese and
nonobese subjects (P  0.05 vs. basal). However, glycerol
release was lower in adipocytes from obese subjects,
compared with nonobese subjects, both at the basal level
and after treatment with isoproterenol or 8-Cl-cAMP, with
these data being statistically signiﬁcant only in visceral
tissue (Fig. 5). Finally, no difference in basal glycerol
release between subcutaneous and visceral adipocytes
was observed, whereas the effects of cAMP and 8-Cl-cAMP
on lipolysis were signiﬁcantly higher in visceral than
subcutaneous adipose tissue from nonobese subjects (P 
0.05).
A positive correlation was found between PKA R2B
mRNA expression and basal PKA activity and isoprotere-
nol-stimulated glycerol release in visceral fat (r  0.430,
r  0.398, respectively; P  0.01) (Fig. 6).
DISCUSSION
Obesity is rapidly increasing in industrialized countries
and, with very few exceptions, the molecular mechanisms
underlying the predisposition to become obese are largely
unknown. In both white and brown adipocytes, cAMP and
the cAMP-dependent PKA are key regulators of lipolysis,
the most important process determining fat storage or
mobilization (4). Data present in the literature to date
indicate that, at least in mice, among the different subunits
constituting the PKA holoenzyme, PKA R2B is the key
regulatory subunit in adipose tissue (4,5,9,15–20). Interest-
ingly, R2B expression is limited to a few tissues known to
regulate energy homeostasis, i.e., the white and brown
adipose tissue and the brain. Studies in R2B knockout
mice revealed an unexpected role for this protein in
regulating energy balance, since these animals remain
remarkably lean even when challenged with a high-fat diet
(5).
Despite this increasing amount of data on murine adi-
pose tissue, and although many groups, including ours,
have clearly demonstrated distinct and cell-speciﬁc roles
for the different PKA isoenzymes in the regulation of
growth control (1,2,12,13,21), very little is known about
the differential role played by the different PKA regulatory
subunits in human fat tissue. In this study, we evaluated
the possible differences in R2B expression, PKA activity,
and lipolysis in subcutaneous and visceral adipose tissue
samples from a large number of obese and nonobese
subjects. Immunohistochemistry demonstrated a strong
immunoreactivity for the R2B protein in all fat tissues
included in our study, whereas the other PKA regulatory
subunits analyzed (R2A and R1A) were expressed at very
low levels. This was true in visceral as well as in subcu-
taneous adipose tissue, and similar data were obtained by
Western blot analysis. This observation ﬁrst demonstrates
that PKA regulatory subunit expression in human adipose
tissue is similar to what was previously observed in
murine adipocytes and supports the hypothesis that PKA
R2B expression is speciﬁc for adipose tissue and few other
cell types (5,9).
Western blot analysis, which better allows the quantiﬁ-
cation of protein expression than immunohistochemistry,
showed that PKA R2B protein expression was dramati-
cally reduced in adipose tissues from obese patients
compared with those from nonobese subjects. This obser-
vation lead us to investigate the pattern of expression also
at the mRNA level. In contrast to what was observed at the
protein level, mRNA of the three subunits was detected in
all the adipose samples analyzed, with R2B being the most
represented regulatory subunit. Nevertheless, while R2A
mRNA was detected at very low levels, PKA R1A seems to
be actively transcribed in all adipose tissues. The discrep-
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R2B mRNA expression in visceral fat from 20 obese and 20 nonobese
subjects (r  0.430, P  0.009, and r  0.398, P  0.002, respectively).
RFU, relative ﬂuorescence units.
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the existence of a high rate of protein instability and
degradation, as already demonstrated for this subunit by
us and others in other cell systems (12,22). Interestingly
and similarly to Western blot data, mRNA levels of the
three regulatory subunits were signiﬁcantly reduced in
obese subjects if compared with nonobese subjects. In
particular, the difference in the expression of PKA R2B
and R1A subunit mRNA between obese and nonobese
subjects was strongly signiﬁcant in both subcutaneous and
visceral adipose tissue samples, whereas the difference in
PKA R2A expression did not reach statistical signiﬁcance.
In agreement with the restricted expression of the R1B
gene (23), this transcript was absent in subcutaneous and
visceral adipose tissues from obese and nonobese subjects
(G.M., personal observations).
We then tried to correlate the expression of PKA regu-
latory subunits with clinical parameters, particularly insu-
lin levels and HOMA-IR. We chose HOMA-IR as a surrogate
marker of insulin resistance, since an oral glucose toler-
ance test was indicated and performed only in obese
patients. Indeed, PKA R2B expression was negatively
correlated to BMI and waist circumference, a clinical
parameter strongly associated with visceral obesity. More-
over, R2B mRNA levels were also negatively correlated
with insulin levels and HOMA-IR, with these correlations
being independent of BMI. These ﬁndings are in agreement
with the only data present in the literature on PKA
expression and function in humans that indicate low levels
of PKA R2B in normal-weight women affected with PCOS
when compared with matched control women, with this
defect being associated with lipolytic catecholamine resis-
tance and insulin resistance in these patients (10,11).
Taking into account that the PRKAR2B promoter has SP-1
transcription factor binding sites, it is tempting to specu-
late that insulin might act on these sites to positively
regulate PRKAR2B transcription (24).
The functional impact of the differential expression of
PKA regulatory subunits in adipose tissues from nonobese
and obese patients was assessed by evaluating PKA activ-
ity and glycerol release in the same samples. Although
both basal and cAMP-stimulated PKA activity were lower
in visceral and subcutaneous protein samples from obese
subjects, compared with what was observed in samples
from nonobese patients, these differences were statisti-
cally signiﬁcant only in visceral adipose tissue. Interest-
ingly, a similarly reduced PKA activity in adipose tissue
from obese patients was observed after stimulation with a
cAMP analog able to selectively activate R2 subunits
(8-Cl-cAMP), suggesting that the low levels of PKA R2B
mRNA and protein detected in these tissues are indeed
associated with a lower PKA activity. Similarly, glycerol
release measured at basal level and after stimulation of
-adrenergic receptor by isoproterenol was signiﬁcantly
reduced in visceral adipocytes from obese patients com-
pared with nonobese subjects. Stimulation with the R2-
selective analog 8-Cl-cAMP induced a signiﬁcant increase
in lipolysis in samples from both obese and nonobese
subjects, with this increase being signiﬁcantly lower in
visceral adipose tissue from obese patients. Taken to-
gether, these data further support the correlation between
real-time PCR and Western blot data and the activation of
the cAMP/PKA pathway and lipolysis. At the moment,
these data do not allow any speculation on the role played
in this circuit by A-kinase anchoring proteins, speciﬁc
anchor proteins that recruit the PKA holoenzyme close to
its substrate/effector proteins, thus directing and modulat-
ing PKA activation.
Our data seem to be partially at variance with the data in
PCOS patients previously reported, in whom the de-
creased expression of R2B in visceral fat cells obtained
from nonobese PCOS patients was associated with a
twofold increase in R1A and in the catalytic subunit and a
consequent twofold increase in catecholamine-induced
adipocyte lipolysis (10), whereas the reduction of R2B in
subcutaneous fat was associated with a reduced lipolytic
responsiveness and sensitivity, mostly due to decreased
expression of the 2-adrenergic receptor (11). However, in
the present study, PKA activity and glycerol release were
investigated by selectively activating R2 subunits, thus
providing novel evidence for a speciﬁc functional impact
of R2B loss in adipocytes, not related to adrenoceptor
downregulation.
In mice, the loss of R2B revealed an unexpected role for
this protein in regulating energy balance (5). In particular,
the absence of this protein is compensated by an increase
in the R1A subunit, which is more sensitive to cAMP
activation and results in a net increase in basal PKA
activity, leading to an increase in metabolic activity, body
temperature, and lipid hydrolysis (5,9). In humans, our
work indicates that the reduction of R2B that accompanies
obesity is not associated with an increase in R1A. Never-
theless, it seems likely that the higher R2B levels found
in nonobese subjects may account, alone, for the PKA
activity required for lipolysis activation in physiological
conditions.
The regulation of human fat cell lipolysis is complex
and, in many ways, species unique. Catecholamines inﬂu-
ence lipolysis through four different adrenoceptor sub-
types, and there are profound regional variations in
adipocyte lipolysis leading to more release of fatty acids
from the visceral than subcutaneous adipose tissue during
hormone stimulation (25–27). These regional variations in
lipolysis have been demonstrated to be further enhanced
in obesity and PCOS and are of importance for dyslipide-
mia, hyperinsulinemia, and glucose intolerance in these
conditions. In particular, a decreased lipolytic effect of
catecholamines in adipose tissue has been repeatedly
demonstrated in obesity and has been suggested as a
cause of excess accumulation of body fat (28,29). Our data
on lipolysis are, at least in part, in contrast with the
prevalent idea that adipocytes from visceral fat depots are
thought to be hyperlipolytic. Nevertheless, relatively few
studies have directly compared lipolysis in visceral versus
subcutaneous adipocytes or adipose tissues, with no unan-
imous ﬁndings. Moreover, although several determinants,
such as polymorphisms of -adrenergic receptor and its
level of expression (30,31) and/or reduced expression and
activity of adipocyte hormone-sensitive and triglyceride
lipases (32,33) have been proposed as responsible for the
lipolytic catecholamine resistance in obesity, the mecha-
nisms of this defect have not been fully understood. We
now propose that differences in PKA expression and
function, which interestingly were particularly evident in
the visceral adipose tissue, may be included among the
complex and multiple players that cause fat accumulation
or mobilization by reducing catecholamine signaling.
In conclusion, our study indicates that, as in mice, R2B
is the key PKA regulatory subunit in human adipose tissue,
both in obese and normal subjects, with no signiﬁcant
differences between visceral and subcutaneous adipose
tissue. Moreover, R2B was dramatically reduced in adipo-
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correlation between R2B expression levels and BMI, waist
circumference, insulin levels, and HOMA-IR. Accordingly,
both basal and cAMP-stimulated PKA activity and glycerol
release were signiﬁcantly lower in adipocytes from obese
patients in comparison with those from nonobese sub-
jects. Our results indicate important BMI-related differ-
ences in R2B expression and PKA activation, which might
be included among the multiple determinants involved in
the different lipolytic response to -adrenergic activation
in obese and nonobese subjects.
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